Unknown

Dataset Information

0

Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis.


ABSTRACT: Blocking lymphocyte trafficking after allogeneic hematopoietic stem cell transplantation is a promising strategy to prevent graft-versus-host disease (GVHD) while preserving the graft-versus-tumor response. Maraviroc, a CCR5 antagonist, has shown promise in clinical trials, presumably by disrupting the migration of effector cells to GVHD target organs. We describe a phosphoflow assay to quantify CCR5 blockade during treatment with maraviroc and used it to evaluate 28 patients in a phase II study. We found that insufficient blockade of CCR5 was associated with significantly worse overall survival (HR,?10.6; 95% CI, 2.2 to 52.0; P?=?.004) and higher rates of nonrelapse mortality (HR,?146; 95% CI, 1.0 to 20,600; P?=?.04) and severe acute GVHD (HR,?12; 95% CI, 1.9 to 76.6; P?=?.009). In addition, we found that pretransplant high surface expression of CCR5 on recipient T cells predicted higher nonrelapse mortality and worse GVHD- and relapse-free survival. Our results demonstrate that pharmacodynamic monitoring of CCR5 blockade unravels interpatient variability in the response to therapy and may serve as a clinically informative biomarker.

SUBMITTER: Huffman AP 

PROVIDER: S-EPMC5826857 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis.

Huffman Austin P AP   Richman Lee P LP   Crisalli Lisa L   Ganetsky Alex A   Porter David L DL   Vonderheide Robert H RH   Reshef Ran R  

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20171020 3


Blocking lymphocyte trafficking after allogeneic hematopoietic stem cell transplantation is a promising strategy to prevent graft-versus-host disease (GVHD) while preserving the graft-versus-tumor response. Maraviroc, a CCR5 antagonist, has shown promise in clinical trials, presumably by disrupting the migration of effector cells to GVHD target organs. We describe a phosphoflow assay to quantify CCR5 blockade during treatment with maraviroc and used it to evaluate 28 patients in a phase II study  ...[more]

Similar Datasets

| S-EPMC5314813 | biostudies-literature
| S-EPMC6445759 | biostudies-literature
| S-EPMC3568501 | biostudies-literature
| S-EPMC6251308 | biostudies-literature
| S-EPMC4259365 | biostudies-literature
| S-EPMC8511171 | biostudies-literature
| S-EPMC7845486 | biostudies-literature
| S-EPMC7986048 | biostudies-literature
| S-EPMC3592842 | biostudies-literature
| S-EPMC3613915 | biostudies-literature